Do analysts prefer LTRN or ERNA?

Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 646.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is LTRN or ERNA more profitable?

Ernexa Therapeutics' return on equity of -305.93% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Ernexa Therapeutics N/A -305.93% -169.86%

Is EVAX or ERNA more profitable?

Evaxion A/S's return on equity of -61.43% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -61.43% -34.23% Ernexa Therapeutics N/A -305.93% -169.86%

Do analysts rate BYSI or ERNA?

Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 646.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BYSI or ERNA more profitable?

BeyondSpring's return on equity of 0.00% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -28.88% Ernexa Therapeutics N/A -305.93% -169.86%

Is ERNA or NXTC more profitable?

NextCure's return on equity of -154.62% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% NextCure N/A -154.62% -100.19%

Is ERNA or ATOS more profitable?

Atossa Genetics' return on equity of -102.99% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% Atossa Genetics N/A -102.99% -85.78%

Ernexa Therapeutics (ERNA) Competitors

$4.02 -0.17 (-4.06%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$4.08 +0.07 (+1.62%)

As of 09/9/2026 07:49 PM Eastern

Compare

ERNA vs. LTRN, EVAX, BYSI, NXTC, and ATOS

Should you buy Ernexa Therapeutics stock or one of its competitors? Ernexa Therapeutics's main competitors and comparable companies include Lantern Pharma (LTRN), Evaxion A/S (EVAX), BeyondSpring (BYSI), NextCure (NXTC), and Atossa Genetics (ATOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ernexa Therapeutics compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Ernexa Therapeutics has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Ernexa Therapeutics	$580K	11.30	-$14.08M	-$14.35	N/A

Lantern Pharma has a beta of 2.3, indicating that its stock price is 130% more volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.61, indicating that its stock price is 161% more volatile than the broader market.

Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 646.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ernexa Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ernexa Therapeutics' return on equity of -305.93% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Lantern Pharma's average media sentiment score of 0.00 equaled Ernexa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Lantern Pharma	Neutral
Ernexa Therapeutics	Neutral

Summary

Ernexa Therapeutics beats Lantern Pharma on 9 of the 12 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, Evaxion A/S's average media sentiment score of 0.00 equaled Ernexa Therapeutics'average media sentiment score.

Company	Overall Sentiment
Evaxion A/S	Neutral
Ernexa Therapeutics	Neutral

Evaxion A/S has higher revenue and earnings than Ernexa Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.64	-$7.71M	-$1.21	N/A
Ernexa Therapeutics	$580K	11.30	-$14.08M	-$14.35	N/A

Evaxion A/S currently has a consensus target price of $11.00, indicating a potential upside of 234.35%. Ernexa Therapeutics has a consensus target price of $30.00, indicating a potential upside of 646.27%. Given Ernexa Therapeutics' higher probable upside, analysts clearly believe Ernexa Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Evaxion A/S's return on equity of -61.43% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Evaxion A/S has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.61, suggesting that its stock price is 161% more volatile than the broader market.

Summary

Evaxion A/S beats Ernexa Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Ernexa Therapeutics compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Ernexa Therapeutics (NASDAQ:ERNA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

In the previous week, BeyondSpring's average media sentiment score of 0.00 equaled Ernexa Therapeutics'average media sentiment score.

Company	Overall Sentiment
BeyondSpring	Neutral
Ernexa Therapeutics	Neutral

BeyondSpring has higher revenue and earnings than Ernexa Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	14.77	-$1.01M	-$0.12	N/A
Ernexa Therapeutics	$580K	11.30	-$14.08M	-$14.35	N/A

BeyondSpring has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, Ernexa Therapeutics has a beta of 2.61, suggesting that its stock price is 161% more volatile than the broader market.

BeyondSpring's return on equity of 0.00% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-28.88%
Ernexa Therapeutics	N/A	-305.93%	-169.86%

Ernexa Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 646.27%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ernexa Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 0.5% of Ernexa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

BeyondSpring beats Ernexa Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Ernexa Therapeutics compare to NextCure?

Ernexa Therapeutics (NASDAQ:ERNA) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 42.7% of NextCure shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 11.9% of NextCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NextCure's return on equity of -154.62% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
NextCure	N/A	-154.62%	-100.19%

Ernexa Therapeutics has a beta of 2.61, meaning that its stock price is 161% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

Ernexa Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 646.27%. NextCure has a consensus price target of $19.00, suggesting a potential upside of 135.44%. Given Ernexa Therapeutics' higher possible upside, equities analysts clearly believe Ernexa Therapeutics is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Ernexa Therapeutics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	11.30	-$14.08M	-$14.35	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

In the previous week, NextCure had 2 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 2 mentions for NextCure and 0 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.00 beat NextCure's score of -0.31 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Ernexa Therapeutics	Neutral
NextCure	Neutral

Summary

Ernexa Therapeutics and NextCure tied by winning 7 of the 14 factors compared between the two stocks.

How does Ernexa Therapeutics compare to Atossa Genetics?

Ernexa Therapeutics (NASDAQ:ERNA) and Atossa Genetics (NASDAQ:ATOS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Ernexa Therapeutics has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	11.30	-$14.08M	-$14.35	N/A
Atossa Genetics	N/A	N/A	-$34.77M	-$3.11	N/A

Ernexa Therapeutics has a beta of 2.61, meaning that its stock price is 161% more volatile than the broader market. Comparatively, Atossa Genetics has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Atossa Genetics shares are owned by institutional investors. 0.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 9.8% of Atossa Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Ernexa Therapeutics' average media sentiment score of 0.00 equaled Atossa Genetics'average media sentiment score.

Company	Overall Sentiment
Ernexa Therapeutics	Neutral
Atossa Genetics	Neutral

Ernexa Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 646.27%. Atossa Genetics has a consensus target price of $20.33, suggesting a potential upside of 747.22%. Given Atossa Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Atossa Genetics is more favorable than Ernexa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atossa Genetics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Atossa Genetics' return on equity of -102.99% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Atossa Genetics	N/A	-102.99%	-85.78%

Summary

Atossa Genetics beats Ernexa Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Ernexa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERNA vs. The Competition

Export

Metric	Ernexa Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.84M	$3.90B	$7.22B	$12.88B
Dividend Yield	N/A	3.62%	2.55%	9.95%
P/E Ratio	-0.28	12.94	271.78	25.29
Price / Sales	11.30	1,459.61	709.75	112.40
Price / Cash	N/A	107.40	77.55	52.32
Price / Book	0.53	15.81	10.63	6.26
Net Income	-$14.08M	-$22.81M	$3.48B	$357.86M
7 Day Performance	-11.45%	-0.25%	-1.38%	-0.39%
1 Month Performance	-4.51%	4.91%	2.17%	-1.28%
1 Year Performance	-87.29%	44.99%	20.74%	11.50%

Ernexa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERNA Ernexa Therapeutics	2.3323 of 5 stars	$4.02 -4.1%	$30.00 +646.3%	-87.3%	$6.84M	$580K	N/A	10
LTRN Lantern Pharma	0.2781 of 5 stars	$1.93 -4.5%	N/A	-56.3%	$25.82M	N/A	N/A	20
EVAX Evaxion A/S	1.5871 of 5 stars	$3.07 +3.0%	$11.00 +258.3%	+17.5%	$24.85M	$7.53M	N/A	60
BYSI BeyondSpring	0.1473 of 5 stars	$0.61 +1.4%	N/A	-67.6%	$24.78M	$1.75M	N/A	80
NXTC NextCure	3.3038 of 5 stars	$7.35 +8.1%	$19.00 +158.5%	+59.2%	$24.56M	N/A	N/A	90	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERNA) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. LTRN, EVAX, BYSI, NXTC, and ATOS

How does Ernexa Therapeutics compare to Lantern Pharma?

Summary

How does Ernexa Therapeutics compare to Evaxion A/S?

Summary

How does Ernexa Therapeutics compare to BeyondSpring?

Summary

How does Ernexa Therapeutics compare to NextCure?

Summary

How does Ernexa Therapeutics compare to Atossa Genetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ernexa Therapeutics (ERNA) Competitors

ERNA vs. LTRN, EVAX, BYSI, NXTC, and ATOS

How does Ernexa Therapeutics compare to Lantern Pharma?

Which has better valuation and earnings, LTRN or ERNA?

Which has more volatility & risk, LTRN or ERNA?

Do analysts prefer LTRN or ERNA?

Is LTRN or ERNA more profitable?

Do insiders and institutionals have more ownership in LTRN or ERNA?

Does the media prefer LTRN or ERNA?

Summary

How does Ernexa Therapeutics compare to Evaxion A/S?

Does the media refer more to EVAX or ERNA?

Which has higher valuation & earnings, EVAX or ERNA?

Do analysts rate EVAX or ERNA?

Is EVAX or ERNA more profitable?

Do insiders and institutionals believe in EVAX or ERNA?

Which has more volatility and risk, EVAX or ERNA?

Summary

How does Ernexa Therapeutics compare to BeyondSpring?

Does the media prefer BYSI or ERNA?

Which has preferable earnings & valuation, BYSI or ERNA?

Which has more risk & volatility, BYSI or ERNA?

Is BYSI or ERNA more profitable?

Do analysts rate BYSI or ERNA?

Do insiders and institutionals hold more shares of BYSI or ERNA?

Summary

How does Ernexa Therapeutics compare to NextCure?

Do insiders and institutionals hold more shares of ERNA or NXTC?

Is ERNA or NXTC more profitable?

Which has more risk & volatility, ERNA or NXTC?

Do analysts recommend ERNA or NXTC?

Which has preferable valuation and earnings, ERNA or NXTC?

Does the media prefer ERNA or NXTC?

Summary

How does Ernexa Therapeutics compare to Atossa Genetics?

Which has stronger earnings & valuation, ERNA or ATOS?

Which has more volatility & risk, ERNA or ATOS?

Do insiders & institutionals hold more shares of ERNA or ATOS?

Does the media prefer ERNA or ATOS?

Do analysts recommend ERNA or ATOS?

Is ERNA or ATOS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERNA vs. The Competition

Ernexa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools